Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Harris Williams & Co. Advises Caprion in its Sale to CGP

Published: Tuesday, July 31, 2012
Last Updated: Monday, July 30, 2012
Bookmark and Share
Caprion provides integrated proteomic biomarker solutions and immune monitoring services.

Harris Williams & Co. has announced the sale of Caprion Proteomics, Inc. (Caprion), the leading provider of integrated proteomic biomarker and target identification solutions and immune monitoring services, to Chicago Growth Partners (CGP).

Caprion was a portfolio company of Great Point Partners (GPP). Harris Williams & Co. acted as an advisor to Caprion.

The transaction closed on July 19, 2012 and was led by James Clark, Turner Bredrup, Geoff Smith, Whit Knier and Paul Hepper from the firm's Healthcare & Life Sciences (HCLS) Group.

"Caprion has established itself as the market leader in providing outsourced proteomic biomarker discovery and immune monitoring services for its growing list of blue-chip pharmaceutical and biotechnology clients. Caprion is well positioned as the pharmaceutical industry continues to outsource critical elements of the drug development process to maximize returns on its research and development spend," said James Clark, a managing director in Harris Williams & Co.'s HCLS Group.

Caprion is the leading provider of proteomics services to many of the largest and most successful pharmaceutical and biotechnology companies, as well as several government research institutions.

Caprion's key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development.

The company's proprietary CellCarta technology is the leading biomarker discovery and validation platform in the growing field of proteomics, and has overcome technical limitations of earlier proteomics technologies by developing and effectively putting into industrial practice a powerful proteomics engine for highly multiplexed, unbiased measurement of protein abundance differences across large sample sets.

GPP, based in Greenwich, CT, is a leading healthcare investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds.

GPP has provided growth equity, growth recapitalization and management buyout financing to more than 100 healthcare companies.

The private equity fund invests in profitable companies across all sectors of the healthcare industry including behavioral health, biologics manufacturing, healthcare services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals and workers' compensation.

For over 25 years and across more than 100 growth companies, the principals of CGP have partnered with quality management teams to help facilitate their growth objectives.

CGP executes its growth-focused investment strategy across four industries: education, tech-enabled services, healthcare and industrial growth. CGP currently manages $1.2 billion of committed capital and has offices in Chicago and La Jolla.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!